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Objective:  To  evaluate  the  efﬁcacy  and  safety  of  perampanel  in  patients  with  drug-resistant  partial  seizures
after the  conversion  from  double-blind  placebo  in  three  phase  III studies  to open-label  perampanel,  and
to assess  the  impact  of perampanel  titration  rates  through  a comparison  of weekly  vs  biweekly  dose
increases.
Methods:  Patients  who  completed  the  three  multinational,  double-blind,  placebo-controlled,  phase  III
core  studies  (studies  304,  305,  or 306)  were  eligible  to  enroll  in  the  extension  study  (study  307).  Patients
completing  the  double-blind  treatment  (6-week  titration,  13-week  maintenance)  with  placebo  (DB-PBO)
or perampanel  (DB-PER)  began  the  extension  study  with  a  16-week  blinded  conversion  period,  during
which  DB-PBO  patients  were  switched  to  perampanel.  Doses  were  titrated  in 2-mg  increments  (biweekly)
to  an  individualized  maximum  tolerated  dose  of perampanel  (up to 12  mg/day).  Patients  then  entered  a
planned,  open-label  treatment  period.
Results:  Perampanel  treatment  during  the  extension  study  reduced  total  seizure  frequency/28  days  rela-
tive  to  the  double-blind  prerandomization  baseline  regardless  of  prior  perampanel  or placebo  treatment
in  the  core  studies.  In the DB-PBO  patients,  median  percent  reductions  in  seizure  frequency  at  the  end
of  the  double-blind  period,  at the  end  of  the  conversion  period,  and  at Weeks  40–52  in  the  open-label
maintenance  period  were  18.6%,  44.3%,  and  55.0%, respectively.  Seizure  control  was  also  improved  in the
DB-PER  patients  during  the  extension  period  compared  to the  end  of the  double-blind  period.  Respon-
der  rates  were  similar  between  the  2 patient  groups  at the  end  of  the  conversion  period.  Perampanel
was  well  tolerated,  with  the  most  common  treatment-emergent  adverse  events  being dizziness,  som-
nolence, weight  increase,  irritability,  fatigue,  and  headache.  For  those  patients  randomized  to the  12  mg
group (DB-PER  12  mg),  78.4%  reached  the  daily  dose  of  10 or 12 mg  by the  end  of the  6-week  titration
period  of  the  double-blind  phase.  By the  end of  the  16-week  conversion  period  of  the extension  study,
64.0%  of  DB-PBO  patients  reached  the  daily  dose  of  10 or 12  mg.  Seizure  frequency  reduction  was  greater
after  the  ﬁrst  13-week  maintenance  period  of  the  extension  study  in  the  DB-PBO  group  compared  to
patients  assigned  to DB-PER  12 mg  during  the  13-week  maintenance  period  of  the  double-blind  study.Abbreviations: AE, adverse event; AED, antiepileptic drug; BMI, body mass index; CP, complex partial seizure; DB, double blind; EMA, European Medicines Agency; FDA,
S  Food and Drug Administration; ITT, intent to treat; MTD, maximum tolerated dose; PBO, placebo; PER, perampanel; SAE, serious adverse event; SG,  secondarily generalized
eizure; SP, simple partial seizure.
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Conclusion:  Patients  who  received  placebo  in  the  phase  III  core  DB  studies  and  transitioned  to  perampanel
in the  open-label  extension  study  (DB-PBO)  achieved  seizure  control  at the end  of the conversion  period
similar  to that  of  patients  who  had been  previously  exposed  to perampanel  (DB-PER)  as  well  as comparable
safety  outcomes.  Patients  who  received  perampanel  during  the  core  studies  and  continued  with  treatment
during  the  extension  study  (DB-PER)  also  showed  sustained  improvements  in  seizure  control  with  long-
term  exposure  to perampanel.
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were given once daily at bedtime with food (Krauss et al., 2013).
The open-label maintenance period of the extension studyntroduction
Despite the availability of more than 20 approved agents for
he treatment of epilepsy, 30% of patients remain drug resistant
Brodie, 2010; Krauss et al., 2013). Therefore, new antiepileptic
rugs (AEDs), particularly those with novel mechanisms of action,
ay  beneﬁt patients with uncontrolled epilepsy (Brodie, 2010). The
MPA receptors are the principal receptors involved in glutamate-
ediated fast excitatory postsynaptic neurotransmission, and they
lay a critical role in the generation and spread of epileptic activity
Rogawski, 2011). Compounds that are AMPA-receptor antago-
ists may  act via a novel mechanism of action to reduce excessive
xcitatory activity and modulate seizure activity in drug-resistant
atients. Moreover, noncompetitive AMPA-receptor antagonists
ave the ability to inhibit receptor activity, even in the presence
f high glutamate concentrations, and may  also have a sustained
ffect in hyperexcitatory states (Rektor, 2013). Perampanel (PER),
he ﬁrst in a novel class of AEDs, is an orally active, noncompet-
tive, selective AMPA-receptor antagonist (Rektor, 2013). PER is
pproved in more than 40 countries for use as an adjunctive therapy
or the treatment of partial seizures, with or without secondarily
eneralized seizures, by the US Food and Drug Administration
FDA) and the European Medicines Agency (EMA) in patients with
pilepsy aged 12 years and older, and by Health Canada in patients
ged 18 years and older with epilepsy that is not satisfactorily con-
rolled with conventional therapy (FYCOMPA SPC 2012; FYCOMPA
roduct Monograph 2013; FYCOMPA US Prescribing Information
014).
The efﬁcacy of PER as an adjunctive therapy was  demonstrated
n three multicenter, double-blind (DB), randomized, parallel
roup, placebo-controlled phase III studies—studies 304, 305, and
06 (“core DB studies”)—each of which enrolled patients with drug-
esistant partial seizures. Data from these studies, which were
ublished previously, indicated that once-daily PER, at doses up to
2 mg/day, signiﬁcantly reduced seizure frequency and increased
esponder rates in patients with drug-resistant partial seizures
French et al., 2012,2013; Krauss et al., 2012; Steinhoff et al., 2013).
atients who completed the three core DB studies were eligi-
le to enroll in an extension study (study 307). Interim results
rom the extension study during the 1–2-year monitoring period
ere previously published and demonstrated that PER had a favor-
ble safety and tolerability proﬁle in patients with drug-resistant
artial seizures over the long term, which was consistent with
he pivotal phase III studies (Krauss et al., 2013). Furthermore,
he decrease in seizure frequency was consistent and maintained
n patients through 1–2 years of PER exposure (Krauss et al.,
013).
Here we report a post hoc analysis of the data from the three
ore DB studies and the extension study. The focus of this anal-
sis is to evaluate the efﬁcacy and safety of PER in patients
ho received placebo (PBO) in the phase III core DB studies and
ransitioned to PER in the extension study. We  further report
n the impact of PER titration rates through a comparison of
eekly vs biweekly titration (core DB studies and extension study,
espectively).©  2015  Published  by Elsevier  B.V.
Methods
Patients and study design
Patients who  were eligible for the core studies were aged 12
years or older with a diagnosis of partial seizures [simple partial
seizure (SP) with motor signs, complex partial seizure (CP), or CP
with secondary generalization] according to the 1981 International
League Against Epilepsy Classiﬁcation of Epileptic Seizures (ILAE,
1981). Patients must have had uncontrolled partial seizures, had ≥2
AED failures in the previous 2 years, and had been taking a stable
type and dose regimen of 1–3 AEDs. During the 6-week prerandom-
ization phase, eligible patients must have had ≥5 partial seizures
(with 2 or more partial seizures per each 3-week period) (French
et al., 2012,2013; Krauss et al., 2012).
Core DB studies
The core DB studies were conducted in 3 phases: the pre-
randomization phase (baseline), the DB treatment phase (6-week
titration period, 13-week maintenance period), and a follow-up
phase of 4 weeks for patients who withdrew prematurely or
who did not elect to enter the extension study (French et al.,
2012,2013; Krauss et al., 2012). Patients were randomized to
once-daily DB treatment with PBO, PER 8 mg,  or PER 12 mg  in
studies 304 (NCT00699972) and 305 (NCT00699582). In study 306
(NCT00700310), patients were randomized to PBO, PER 2 mg,  PER
4 mg,  or PER 8 mg.  Patients continued to receive a stable treat-
ment regimen of 1–3 concomitant AEDs throughout the study
(French et al., 2012,2013; Krauss et al., 2012). During the titra-
tion period, PER doses were increased by 2 mg  per week to the
randomized dose, and dose reductions were permitted for intol-
erability. Patients treated with PER continued treatment with the
dose achieved during titration throughout the maintenance period.
Patients who  completed one of these phase III studies of adjunctive
PER were eligible to continue in the extension study (Montouris
et al., 2012).
Extension study
The extension study (307; NCT00735397) was comprised of a
16-week blinded conversion period, a planned 256-week main-
tenance period, and a 4-week follow-up phase (Krauss et al.,
2013,2014). In the 16-week blinded conversion period, patients
randomized to receive PBO in the core studies (DB-PBO) were
given PER 2 mg/day and titrated upward in 2-mg increments every
2 weeks (in contrast to weekly titration in the core DB studies).
Titration continued to the patient’s individualized maximum tol-
erated dose (MTD), up to 12 mg/day. Patients receiving PER during
the core studies (DB-PER) continued to receive PER on a blinded
basis. Those DB-PER patients not already receiving 12 mg/day were
titrated upward in 2-mg increments every 2 weeks to their individ-
ualized MTD  (up to 12 mg/day) (Krauss et al., 2013,2014). All dosesbegan upon completion of the blinded conversion/titration period.
Patients remained on the MTD  achieved at the end of the
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onversion period unless further dose adjustment for tolerability
nd/or efﬁcacy was necessary (Krauss et al., 2013,2014). Patients
emained on the same 1–3 concomitant AEDs given during the
ore DB studies; however, during the extension study, concomi-
ant AEDs could be discontinued or changed at the investigator’s
iscretion (Krauss et al., 2013,2014). Patients began entering the
xtension study in October of 2008; the end date for the anal-
sis was October 2011 (Krauss et al., 2014). Patients who could
ot tolerate at least 2 mg/day PER withdrew from the study.
tudy visits were scheduled every 4 weeks during the conversion
eriod and increased to every 3 months thereafter (Krauss et al.,
013,2014).
The core DB studies and extension study were performed
n accordance with the International Conference on Harmoni-
ation/Good Clinical Practice guidelines and the Declaration of
elsinki (French et al., 2012,2013; Krauss et al., 2012,2013,2014).
he study protocols, amendments, and informed consents were
eviewed by national regulatory authorities in each coun-
ry and by independent ethics committees or institutional
eview boards for each site. All patients provided informed
onsent prior to participating in the studies (Krauss et al.,
013,2014).
fﬁcacy end points
Patients with partial seizures recorded seizure frequency and
ype in daily diaries (SP with or without motor signs, CP, and partial
eizures with secondary generalization [SG]) (Steinhoff et al., 2013).
he primary efﬁcacy end points were the median percent reduc-
ion in total seizure frequency (all partial seizures) per 28 days of
reatment relative to the DB prerandomization phase baseline, and
he percentage of patients who experienced a ≥50% reduction from
aseline in seizure frequency per 28 days of treatment (responder
ate) (Krauss et al., 2013; Montouris et al., 2012; Steinhoff et al.,
013). Secondary efﬁcacy end points included percent change in CP
lus SG (CP + SG) frequency per 28 days during treatment relative
o baseline. Other exploratory efﬁcacy variables included percent
hange in the frequency per 28 days of SG during treatment relative
o baseline, and responder rate based on CP + SG and SG. Additional
nalysis of the DB-PBO group was conducted using the 13-week
aintenance period seizure frequency of the core DB studies as
aseline.
afety assessments
Adverse events (AEs) were recorded throughout the studies.
afety assessments included examinations of the incidence rates
f AEs, serious adverse events (SAEs), and withdrawals due to AEs
Montouris et al., 2012). AEs were considered to be “treatment-
mergent” if they started on or after the ﬁrst PER dose date (core
hase III or extension study) and prior to 30 days after the last dose,
r if they were present prior to treatment but worsened in severity
uring the study (Krauss et al., 2013).
tatistical analyses
All seizure-related analyses for the extension study were per-
ormed on the intent-to-treat (ITT) analysis set, which was  deﬁned
s all patients who provided informed consent for the extension
tudy, received at least 1 dose of PER in the extension study, and had
alid seizure data during the PER treatment duration (DB and/or
xtension) (Krauss et al., 2013,2014). The ITT population for the
ore DB studies consisted of the group of subjects who  were ran-
omized to and received at least 1 dose of the study drug and had
ny seizure data during the DB phase.arch 114 (2015) 131–140 133
The safety analysis set was deﬁned as all patients who received
at least 1 dose of PER in the extension study and had at least 1
postdose safety assessment during this period (Krauss et al., 2013).
Safety data are presented by predeﬁned ranges of maximum daily
dose and include data from the entire PER treatment duration. For
AE analyses, PER treatment duration was deﬁned as all exposure to
PER in the DB and extension studies (Krauss et al., 2013).
Results
Patient disposition and characteristics
A total of 1218 eligible patients (96.4% of DB completers) pro-
vided informed consent and were enrolled in the extension study
(Fig. 1), which included 311 patients from study 304 (105 DB-PBO,
206 DB-PER), 312 patients from study 305 (118 DB-PBO, 194 DB-
PER), and 595 patients from study 306 (157 DB-PBO, 438 DB-PER).
Of the 1218 patients, 380 were previously randomized to PBO and
838 were randomized to PER in the core DB studies (Krauss et al.,
2014).
The safety analysis set included 1216 patients, of which 92.3%
of patients received a maximum daily dose of PER 10 or 12 mg/day
in the extension study. The mean ± standard deviation dose of PER
in the safety analysis set across the entire open-label maintenance
period was  10.6 ± 2.3 mg (Krauss et al., 2014).
The demographic characteristics and baseline seizure history of
patients were comparable between DB-PBO and DB-PER treatment
groups and are summarized in Table 1.
Efﬁcacy
All efﬁcacy results in this study used the ITT analysis data set. The
percent reduction in total seizure frequency per 28 days during the
extension study (conversion and Weeks 1–52 of the maintenance
period) relative to DB prerandomization baseline is summarized
in Fig. 2 by previous DB treatment (DB-PBO or DB-PER). At the
time of entry into the extension study, the median percent reduc-
tion in total seizure frequency per 28 days relative to baseline was
18.6% for patients in the DB-PBO group and 31.7% for patients in the
DB-PER group. Relative to the prerandomization phase of the core
studies, use of PER in the extension study, regardless of prior PBO
or PER administration, decreased total seizure frequency. By the
end of the 16-week conversion period during the extension study,
patients in the DB-PBO group achieved reductions in seizure fre-
quency similar to those in the DB-PER group: 44.3% for DB-PBO and
41.4% for DB-PER (Fig. 2A). The decrease in seizure frequency was
maintained through the ﬁrst 52 weeks of the open-label mainte-
nance period (Weeks 1–52), with reductions of 55.0% in the DB-PBO
group (n = 209) and 53.9% in the DB-PER group (n = 485) at Weeks
40–52.
Additionally, by the end of the extension conversion period,
seizure frequency reductions of CP + SG or SG in the DB-PBO group
were similar to those in the DB-PER group (Fig. 2B and C). These
improvements were generally maintained through the ﬁrst 52
weeks of the open-label maintenance period of the extension study,
although reduction in SG seizure frequency was greater in DB-PER
during Weeks 40–52.
Similarly, relative to the prerandomization baseline of the core
DB studies, use of PER in the extension study increased the respon-
der rate (Fig. 3). At the time of entry into the extension study,
the responder rate for patients in the DB-PBO group was  20.3%;
it increased to 44.3% by the end of the 16-week blinded conver-
sion period. For patients in the DB-PER group, the responder rate
increased from 34.0% at the time of entry into the extension study
to 43.4% by the end of the 16-week blinded conversion period of the
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Figure 1. Patient disposition in studies 304, 305, and 306 and the extension study.a Sources: French et al., 2012,2013; Krauss et al., 2012,2013; Montouris et al., 2012). DB,
double blind; ITT, intent to treat; PBO, placebo; PER, perampanel; MTD, maximum tolerated dose.aDB-PBO = patients who received placebo in the phase III core DB studies
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reatment during the extension study.
xtension study. The responder rates were also maintained in both
roups through the ﬁrst 52 weeks of the open-label maintenance
eriod, with similar responder rates at Weeks 40–52 (Fig. 3A). Addi-
ionally, the responder rates in the DB-PBO group for CP + SG and
G increased to a level similar to the responder rates in the DB-PER
roup at the end of the 16-week blinded conversion period (Fig. 3B
able 1
emographic and baseline characteristics of patients in the extension study by previous 
Category DB-PBO
(N = 379)
DB-PER 2 mg
(N = 147)
DB
(N 
Median age, years (range)b 33 (12–76) 31 (13–65) 32
Sex,  n (%)
Male 200 (52.8) 66 (44.9) 79
Race, n (%)
White 294 (77.6) 92 (62.6) 93
Black or African American 9 (2.4) 0 0
Asian 41 (10.8) 32 (21.8) 33
Chinese 26 (6.9) 22 (15.0) 27
American Indian or Alaska Native 0 0 0
Other 9 (2.4) 1 (<1.0) 1
Ethnicity, n (%)
Hispanic or Latino 67 (17.7) 7 (4.8) 8
Median BMI, kg/m2 (range)b 23.88 (14.0–50.5) 23.41 (16.4–41.7) 23.82
Seizure type, n (%)c
Simple partial without motor
signs
133 (35.1) 42 (28.6) 43
Simple partial with motor signs 112 (29.6) 43 (29.3) 50
Complex partial 326 (86.0) 125 (85.0) 129
Complex partial with secondary
generalization
274 (72.3) 97 (66.0) 107
a DB-PBO = patients who  received placebo in the phase III core DB studies and transitione
erampanel during the core studies and continued with perampanel treatment during th
b Age at informed consent for the preceding DB study.
c BMI and seizure type are at baseline in the preceding DB study.
MI, body mass index; DB, double blind; ITT, intent to treat; PBO, placebo; PER, perampaho received perampanel during the core studies and continued with perampanel
and C), which was  maintained throughout the ﬁrst 52 weeks of the
open-label maintenance period.In study 304, an unusually high placebo responder rate was
observed among patients in the Central and South America region
(CA/SA) compared to North American sites (French et al., 2012).
To ensure that this high placebo response did not impact the
DB treatment assignment: ITT set.a
-PER 4 mg
= 154)
DB-PER 8 mg
(N = 356)
DB-PER 12 mg
(N = 181)
DB-PER overall
(N = 838)
 (12–68) 34 (12–72) 32 (12–66) 33 (12–72)
 (51.3) 177 (49.7) 89 (49.2) 411 (49.0)
 (60.4) 282 (79.2) 150 (82.9) 617 (73.6)
 7 (2.0) 7 (3.9) 14 (1.7)
 (21.4) 33 (9.3) 16 (8.8) 114 (13.6)
 (17.5) 21 (5.9) 0 70 (8.4)
 4 (1.1) 1 (<1.0) 5 (<1.0)
 (<1.0) 9 (2.5) 7 (3.9) 18 (2.1)
 (5.2) 66 (18.5) 48 (26.5) 129 (15.4)
 (12.1–38.4) 24.93 (15.1–45.3) 24.58 (15.9–43.9) 24.44 (12.1–45.3)
 (27.9) 121 (34.0) 53 (29.3) 259 (30.9)
 (32.5) 110 (30.9) 54 (29.8) 257 (30.7)
 (83.8) 305 (85.7) 156 (86.2) 715 (85.3)
 (69.5) 249 (69.9) 134 (74.0) 587 (70.0)
d to perampanel in the open-label extension study; DB-PER = patients who  received
e extension study.
nel.
G. Montouris et al. / Epilepsy Research 114 (2015) 131–140 135
Figure 2. Median % reduction in seizure frequency/28 days from the DB prerandomization baseline during treatment duration for all partial seizures (A), CP + SG (B), and only
SG  (C).a *Percent change from prerandomization baseline seizure frequency/28 days during the maintenance period of the core studies (304, 305, and 306). CP, complex partial
seizure; PER, perampanel; SG, secondarily generalized seizure.aDB-PBO = patients who received placebo in the phase III core DB studies and transitioned to perampanel in
the  open-label extension study; DB-PER = patients who  received perampanel during the core studies and continued with perampanel treatment during the extension study.
136 G. Montouris et al. / Epilepsy Research 114 (2015) 131–140
Figure 3. Responder rates (% of patients experiencing ≥50% reduction in seizure frequency) from the DB prerandomization period through the indicated treatment duration
f ntenan
p laceb
e es and
e
o
a
por  all partial seizures (A), CP + SG (B), and only SG (C).a *Responder rate during mai
erampanel; SG, secondarily generalized seizure.aDB-PBO = patients who received p
xtension study; DB-PER = patients who received perampanel during the core studivaluation of the conversion or the reduction in seizure frequency
bserved during the extension study with PER, we undertook
dditional analyses that excluded data from sites in CA/SA (Sup-
lementary Figure 1). At the time of entry into the extension study,ce period of the core studies (304, 305, and 306). CP, complex partial seizure; PER,
o in the phase III core DB studies and transitioned to perampanel in the open-label
 continued with perampanel treatment during the extension study.the median percent reduction in total seizure frequency per 28 days
relative to baseline in the population excluding CA/SA was 15.1%
for patients in the DB-PBO group and 31.7% for patients in the DB-
PER group (Supplementary Fig. 1A). Except for the median percent
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Table  2
Overall incidence of TEAEs: safety analysis set.a
Category DB-PBO
(N = 378),
n  (%)
DB-PER
(N = 838),
n (%)
TEAEs 343 (90.7) 767 (91.5)
Treatment-related TEAEs 304 (80.4) 689 (82.2)
Severe TEAEs 69 (18.3) 151 (18.0)
Treatment-emergent SAEs* 77 (20.4) 150 (17.9)
Deaths 3 (0.8) 2 (0.2)
Other SAEs 74 (19.6) 149 (17.8)
Life-threatening 2 (0.5) 12 (1.4)
Requires or prolongs hospitalization 71 (18.8) 135 (16.1)
Persistent/signiﬁcant disability/incapacity 2 (0.5) 4 (0.5)
Congenital anomaly/birth defect 0 0
Important medical events 6 (1.6) 19 (2.3)
TEAEs leading to dose adjustments 208 (55.0) 401 (47.9)
TEAEs leading to study/study drug withdrawal 75 (19.8) 120 (14.3)
TEAEs leading to dose reduction 162 (42.9) 321 (38.3)
TEAEs leading to dose interruption 8 (2.1) 39 (4.7)
* One subject had multiple SAEs and is summarized in both Deaths and ther SAEs.
Adverse events were summarized across the entire PER exposure.
a DB-PBO = patients who  received placebo in the phase III core DB studies and
transitioned to perampanel in the open-label extension study; DB-PER = patients
who  received perampanel during the core studies and continued with perampanel
t
D
t
r
i
t
d
i
r
u
i
t
F
i
P
P
t
t
p
p
a
t
D
i
p
t
(
t
l
S
b
p
S
i
t
T
f
l
(
Table 3
Rates of the most common TEAEs with an incidence ≥5% in the DB-PBO group
compared with the DB-PER group (safety analysis set).a
TEAEs DB-PBO
(N = 378),
n  (%)
DB-PER
(N = 838),
n (%)
Dizziness 171 (45.2) 398 (47.5)
Somnolence 70 (18.5) 188 (22.4)
Weight increase 44 (11.6) 88 (10.5)
Irritability 41 (10.8) 99 (11.8)
Fatigue 41 (10.8) 118 (14.1)
Headache 38 (10.1) 184 (22.0)
Ataxia 31 (8.2) 49 (5.8)
Fall  31 (8.2) 68 (8.1)
Nasopharyngitis 28 (7.4) 86 (10.3)
Gait  disturbance 27 (7.1) 48 (5.7)
Convulsion 27 (7.1) 69 (8.2)
Depression 22 (5.8) 44 (5.3)
Head injury 21 (5.6) 26 (3.1)
Dysarthria 21 (5.6) 35 (4.2)
Aggression 21 (5.6) 41 (4.9)
Nausea 21 (5.6) 75 (8.9)
Adverse events were summarized across the entire PER exposure.
a DB-PBO = patients who received placebo in the phase III core DB studies and
transitioned to perampanel in the open-label extension study; DB-PER = patients
who received perampanel during the core studies and continued with perampanelreatment during the extension study.
B, double blind; PBO, placebo; PER, perampanel; SAE, serious adverse event; TEAE,
reatment-emergent adverse event.
eduction in seizure frequency seen in the DB-PBO group at entry
nto the extension study, which was lower than that reported in
he total population (18.6%, Fig. 2A), results at all other time points
uring the extension study were comparable between the data set
n which CA/SA was excluded and the total population. Similarly,
elative to the prerandomization baseline of the core DB studies,
se of PER in the extension study increased the responder rate
n the population excluding CA/SA (Supplementary Fig. 1B), and
his was comparable to the data for the total population (shown in
ig. 3). These results suggest that the high placebo response seen
n study 304 (French et al., 2012) did not impact the efﬁcacy of
ER in patients who transitioned during the extension study (DB-
BO), as seizure reduction and responder rates were comparable
o those seen in DB-PER patients, even when the CA/SA popula-
ion was excluded, starting from the end of the blinded conversion
eriod and continuing throughout the ﬁrst 52-week maintenance
eriod during the extension study.
To evaluate the impact of conversion to perampanel, an
dditional analysis in the DB-PBO group was conducted using
he 13-week maintenance period seizure frequency of the core
B studies as baseline. The efﬁcacy results demonstrated an
mprovement for patients in the DB-PBO group that converted to
erampanel during the open-label extension study. At the end of
he 16-week blinded conversion, the median percent reduction
relative to the 13-week maintenance period seizure frequency of
he core DB studies) was 27.1%, and by Weeks 40–52 of the open-
abel maintenance period the median percent reduction was  39.6%.
imilarly, the responder rate was 28.0% and 40.9% at the end of the
linded conversion period and Weeks 40–52 of the maintenance
eriod in the open-label study, respectively.
afety
The incidence of treatment-emergent adverse events (TEAEs)
n the extension study safety population, based on their prior
reatment assignment during the core DB studies, is shown in
able 2. TEAEs during the entire PER exposure (extension period
or DB-PBO, and DB and extension period for DB-PER) were simi-
ar between DB-PBO patients (90.7%, n = 343) and DB-PER patients
91.5%, n = 767). Treatment-emergent SAEs occurred in 20.4%treatment during the extension study.
DB, double blind; PBO, placebo; PER, perampanel; TEAE, treatment-emergent
adverse event.
(n = 77) DB-PBO patients and 17.9% (n = 150) DB-PER patients. Study
withdrawal rates due to TEAEs during the entire PER exposure
were slightly higher for DB-PBO patients (19.8%, n = 75) compared
to withdrawal rates for DB-PER patients (14.3%, n = 120).
Incidence rates of the most common TEAEs (≥5%) for DB-PBO
patients were generally similar to those for DB-PER patients dur-
ing the entire PER exposure (Table 3), although somnolence (18.5%
vs 22.4%), fatigue (10.8% vs 14.1%), nasopharyngitis (7.4% vs 10.3%)
and nausea (5.6% vs 8.9%) were less frequent in the DB-PBO group.
The incidence of headache in the DB-PBO group was approximately
half that of the DB-PER group, with rates of 10.1% and 22.0%, respec-
tively, whereas the incidence of ataxia and head injury in the
DB-PBO group (8.2% and 5.6%, respectively) was  slightly greater
than in the DB-PER group (5.8% and 3.1%, respectively) throughout
the entire PER exposure.
Impact of the rate of titration on efﬁcacy and safety
The impact of a slower titration rate of PER on the safety and efﬁ-
cacy was  analyzed by comparing core DB study patients previously
assigned to the DB-PER 12-mg treatment group (weekly titration)
with patients in the DB-PBO treatment group who switched to PER
in the extension study (biweekly titration). At the completion of the
16-week conversion period in the extension study, 64.0% of the DB-
PBO group completed the uptitration to a dose level of 10–12 mg;
in comparison, 78.4% of the DB-PER 12-mg group completed the 6-
week titration DB period to a dose level of 10–12 mg  (Table 4). At the
end of the ﬁrst 13-week maintenance period on PER, 71.2% of DB-
PBO patients during the extension study and 74.2% of DB-PER 12-
mg group during the core DB study were on 10–12 mg/day (Table 4).
Despite the longer exposure to PER, the discontinuation rates
due to TEAEs were similar for the DB-PBO group in the 16-week
conversion period in the extension study and the DB-PER 12-mg
group in the 6-week DB titration period (9.5% vs 9.8%) (Table 4).
The discontinuation rates due to TEAEs in the ﬁrst 13-week main-
tenance period of PER exposure were 3.3% for the DB-PBO group
and 10.0% for the DB-PER 12-mg group (Table 4). During the same
period, the rates due to other reasons for discontinuation, which
included subject choice and inadequate therapeutic effect, were
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Table 4
Discontinuation rate and completed doses in DB-PBO compared with DB-PER 12 mg based on last dose (safety analysis set).a
Parameter Titration period Maintenance period
DB-PBO (N = 378) DB-PER 12 mg (N = 255) DB-PBO (N = 306) DB-PER 12 mg (N = 221)
16-week conversion
period (biweekly
uptitration)
6-week titration period
(weekly uptitration)
Weeks 1–13
maintenance period
(extension study)
13-week maintenance
period (DB study)
Discontinuations due to adverse event, n (%) 36 (9.5) 25 (9.8) 10 (3.3) 22 (10.0)
Discontinuation due to other reasons, n (%) 36 (9.5) 9 (3.5) 15 (4.9) 6 (2.7)
Completed period with last dose of, n (%);
10–12 mg/day 242 (64.0) 200 (78.4) 218 (71.2) 164 (74.2)
≤8  mg/day 64 (16.9) 21 (8.2) 63 (20.6) 29 (13.1)
a DB-PBO = patients who  received placebo in the phase III core DB studies and transitioned to perampanel in the open-label extension study; DB-PER = patients who  received
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B,  double blind; PBO, placebo; PER, perampanel.
.9% in the DB-PBO group compared to 2.7% in the DB-PER 12-mg
roup (Table 4).
The ﬁrst 13-week maintenance period of PER treatment for the
B-PBO group (Weeks 1–13 in the extension study) and for the
B-PER 12-mg group (13-week maintenance period of the core
B study) were compared for PER efﬁcacy. Median percent reduc-
ion in seizure frequency was 48.2% in the DB-PBO group (n = 303)
ompared to 33.4% in the DB-PER 12-mg group (n = 219). The cor-
esponding responder rate in the 13-week maintenance period for
he DB-PBO group was 48.2%, which was higher than the responder
ate of 37.9% for the DB-PER 12-mg group. However, throughout the
rst 52 weeks of the open-label maintenance period of the exten-
ion study, the percent seizure reduction (Fig. 4A) and responder
ate (Fig. 4B) were similar between patients in the DB-PBO group
nd patients previously assigned to DB-PER 12-mg.
iscussion
This extension study post hoc analysis further highlights the
fﬁcacy of PER in patients with drug-resistant partial seizures,
peciﬁcally in patients who converted from placebo during the core
B phase III studies to PER during the open-label study (DB-PBO).
B-PBO patients who transitioned to PER during the extension
tudy achieved seizure reduction and responder rates comparable
o DB-PER patients, starting from the end of the blinded conver-
ion period and maintained throughout the ﬁrst 52 weeks of the
aintenance period of the extension study. In addition, the ﬁnd-
ngs of the extension study show that seizure control was sustained
or patients from the core studies who continued PER. PER also
educed CP + SG and SG frequency and improved responder rates
n patients from the DB-PBO group, and these results were compa-
able to those of the DB-PER group. These ﬁndings were consistent
ith results from the previously published three core phase III DB
tudies (French et al., 2012,2013; Krauss et al., 2012; Steinhoff et al.,
013), further supporting the efﬁcacy of PER. Similar efﬁcacy results
ere seen when patients from the CA/SA population were excluded
n an additional analysis conducted to account for the high placebo
esponse seen in study 304. In addition to presenting efﬁcacy data
s “relative to prerandomization baseline seizure frequency,” a
urther analysis using seizure frequency during the maintenance
eriod of the core DB studies as reference was conducted to eval-
ate the impact of conversion to PER and to provide additional
nformation on the real treatment effect in the DB-PBO group. The
esults show that, whether using prerandomization seizure fre-
uency or seizure frequency of the last 13 weeks of the DB studies
maintenance period), patients in the DB-PBO group who  were tak-
ng placebo and 1–3 concomitant AEDs during the core DB studies
xperienced an improvement in seizure frequency when converted
o PER during the open-label extension study.e extension study.
Because PER is a novel AMPA receptor antagonist that has been
approved by the FDA, the EMA, and Health Canada, additional anal-
ysis of its long-term safety and tolerability are important. The
incidence of TEAEs reported in the DB-PBO and DB-PER groups
was similar during the entire PER exposure (extension study for
DB-PBO, and DB and extension study for DB-PER). Dizziness, som-
nolence, weight increase, irritability, fatigue, and headache had
the highest incidence rates in both patient groups. The rates of
TEAEs leading to withdrawal for both patient groups were in
the range reported in the core studies (French et al., 2012,2013;
Krauss et al., 2012; Steinhoff et al., 2013). The incidence of SAEs
was similar between the 2 groups during the entire PER expo-
sure.
The extension study provided physicians with greater ﬂexibil-
ity in dosing and titration rates of PER when compared with the DB
studies, as patients were titrated biweekly in the extension study
to their individualized MTD—an approach that resembles real-life
clinical practice. A slightly higher percentage of patients reached
the dose of 10–12 mg/day in the DB-PER 12-mg group at the end
of the 6-week titration period in the DB core studies than in the
DB-PBO group by the end of the 16-week conversion period in
the extension. This difference may  have been due in part to the
DB design and forced titration over the 6-week period, although
dose reductions were permitted for intolerability. Nonetheless, the
majority of patients (92.3%) in the safety analysis set of the exten-
sion study received a maximum daily dose of PER 10 mg  or 12 mg
(Krauss et al., 2014). The rate of titration (weekly in the core DB
studies vs biweekly in the extension study) did not affect the over-
all safety proﬁle of PER, as the discontinuation rates due to TEAEs
were similar between the DB-PBO group in the conversion period
of the extension study and the DB-PER 12-mg group during the DB
titration period, despite the longer exposure. These data demon-
strate the safety of PER in patients who were not previously exposed
to PER. A comparison of efﬁcacy data for the ﬁrst 13-week main-
tenance period of PER suggests that a slower titration improves
efﬁcacy. Alternatively, the longer PER exposure in the DB-PBO
patients (due to 16-week conversion period) compared to DB-PBO
12-mg group (6-week titration) may  also explain the difference in
efﬁcacy during the ﬁrst 13-week maintenance period. However,
further analysis shows the reduction in seizure frequency was sim-
ilar between the two  groups with exposure to PER throughout the
ﬁrst 52 weeks of the maintenance period of the extension study.
In conclusion, the ﬁndings of the post hoc analysis showed that
patients who received PBO in the phase III core DB studies and tran-
sitioned to PER in the extension study (DB-PBO) achieved similar
seizure control at the end of the conversion period, and thereafter
efﬁcacy and safety were comparable to patients who  had been pre-
viously exposed to PER (DB-PER). In addition, seizure control was
maintained in patients who received PER during the core studies
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Figure 4. Median % reduction in total seizure frequency/28 days (A) and responder rate (B) from the DB prerandomization baseline during the extension open-label
m bo; PE
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eaintenance period in DB-PBO and DB-PER 12-mg.a DB, double-blind; PBO, place
tudies and transitioned to perampanel in the open-label extension study; DB-PER
nd  continued with perampanel treatment during the extension study.
nd continued with treatment during the extension study, regard-
ess of titration rate. Taken together, these results demonstrate the
ong-term efﬁcacy and safety of PER.
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